Therapy Areas: Oncology
Sirtex performs first procedure of selective internal radiation therapy using SIR-Spheres Y-90 resin microspheres
12 October 2021 -

Sirtex, a global healthcare business with offices in the United States, Australia, Europe and Asia, announced on Monday that it has successfully performed the first procedure of selective internal radiation therapy using SIR-Spheres Y-90 resin microspheres for a patient with hepatocellular carcinoma in China, effective 28 September 2021.

The company has achieved this milestone with the support of its shareholder China Grand Pharmaceutical and Healthcare Holdings Limited.

Dr Jiahong Dong, a specialist in hepatobiliary pancreatic surgery and liver transplantation, and his team at Boao Super Hospital in the Hainan Province have carried out the procedure.

In November 2020, the National Medical Products Administration (NMPA) of the People's Republic of China accepted the Sirtex new drug application (NDA) of SIR-Spheres Y-90 resin microspheres for the treatment of colorectal cancer liver metastases.

Login
Username:

Password:


Related Headlines